DRUG ALLERGY IN SYSTEMIC MASTOCYTOSIS
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Mastocytosis is a rare clonal myeloid neoplasm characterized by abnormal accumulation of mast cells in one or more tissues and inappropriate acute and/or chronic release of mast cell mediators. This dysregulated mast cell activation results in a broad and heterogeneous clinical spectrum, ranging from cutaneous manifestations to recurrent and potentially life-threatening anaphylaxis. One of the most challenging aspects of disease management is the heightened concern regarding medications and med-ical procedures that are perceived to trigger mast cell activation. Consequently, many patients with mastocytosis are labeled as having “drug allergy” without adequate confirmation. This may lead to delayed treatment or restricted access to first-line therapies in critical clinical settings, including severe infections, surgical interventions, contrast-enhanced imaging procedures, anesthesia, and vaccination programs. As such, drug hypersensitivity reactions represent an important unmet clinical need in the management of patients with systemic mastocytosis. This section summarizes current evidence regard-ing the epidemiology of drug hypersensitivity in systemic mastocytosis, underlying pathophysiological mechanisms, and practical approaches to evaluation and management. Immediate drug reactions in mastocytosis may occur through classical IgE-mediated immune mechanisms or via IgE-independent pathways. These include direct mast cell activation mediated by Mas-related G protein–coupled recep-tor X2 (MRGPRX2), as well as other pharmacological and complement-mediated mechanisms. This mechanistic heterogeneity highlights the importance of careful clinical phenotyping, detailed histo-ry-taking, and structured allergy assessment rather than the generalized avoidance of medications often applied in patients with mastocytosis. Available cohort studies indicate that most patients with systemic mastocytosis can tolerate many commonly used medications. In contrast, severe drug-related reactions tend to occur in selected high-risk subgroups and are frequently reported before the diagnosis of masto-cytosis is established. These observations support the need for systematic post-diagnosis reassessment and confirmation-based decision-making. Nevertheless, because existing data are largely derived from retrospective studies with limited sample sizes, larger prospective studies are required to better de-fine the true incidence, risk determinants, and the most effective preventive strategies across different mastocytosis subtypes. In conclusion, careful history-taking and documentation, evidence-based di-agnostic testing, removal of incorrect drug allergy labels (delabeling), and individually risk-tailored supervised re-exposure and/or premedication strategies can reduce unnecessary drug restrictions and expand safe therapeutic options for patients with systemic mastocytosis.
Fields of Study & Subjects
Mast cells and histamine
Drug-Induced Adverse Reactions
Food Allergy and Anaphylaxis Research
Publication details
- Journal / source
- Turkiye Klinikleri eBooks
- Pages
- 171–183
- Publication date
- 1 January 2026
- Language
- EN
- Document type
- Book chapter